Alnylam Showcases Advanced RNAi Therapy Data for Heart Failure at ESC Congress

Biotech firm Alnylam presented new clinical findings at the European Society of Cardiology 2026 conference, highlighting the efficacy of its RNA interference drugs in treating transthyretin amyloid cardiomyopathy.

30 Aug, 13:12 — 30 Aug, 13:12

Post Share

Sources

Showing 1 of 1 sources

morningstar1d ago

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings - Morningstar

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings Morningstar

Read full article →

Alnylam Showcases Advanced RNAi Therapy Data for Heart Failure at ESC Congress

Sources

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings - Morningstar

Related Stories

Nigeria Reports 4.43 Percent Economic Growth in Second Quarter

Prediction Platform Kalshi Permanently Bans George Santos Over Insider Trading

Trump Administration Announces Major Oil Deal with Venezuela and Drug Pricing Pacts

Aon Agrees to Acquire USI Insurance Services in $17 Billion Deal